<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100952">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063659</url>
  </required_header>
  <id_info>
    <org_study_id>LX1606.1-303-CS</org_study_id>
    <secondary_id>LX1606.303</secondary_id>
    <nct_id>NCT02063659</nct_id>
  </id_info>
  <brief_title>Telotristat Etiprate for Carcinoid Syndrome Therapy</brief_title>
  <acronym>TELECAST</acronym>
  <official_title>A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on
      the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid
      (5-HIAA) levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of daily bowel movements</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool consistency</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of cutaneous flushing episodes</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in abdominal pain</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the frequency of rescue short-acting, somatostatin analog used to treat carcinoid syndrome symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinoid Syndrome</condition>
  <arm_group>
    <arm_group_label>250 mg telotristat etiprate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One telotristat etiprate (250 mg) tablet and one placebo tablet administered three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg telotristat etiprate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two telotristat etiprate (250 mg) tablets administered three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets administered three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat etiprate tablets (250 mg)</intervention_name>
    <description>Telotristat etiprate (250 mg) in tablet form.</description>
    <arm_group_label>250 mg telotristat etiprate</arm_group_label>
    <arm_group_label>500 mg telotristat etiprate</arm_group_label>
    <other_name>LX1606</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo in tablet form</description>
    <arm_group_label>250 mg telotristat etiprate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  All patients of reproductive potential must agree to use an adequate method of
             contraception during the study and for 12 weeks after the Follow-up visit.

          -  Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor

          -  Documented history of carcinoid syndrome

          -  Patient is able and willing to provide written informed consent prior to
             participation

        Exclusion Criteria:

          -  Presence of diarrhea attributed to any condition other than carcinoid syndrome.

          -  Presence of 12 or more watery bowel movements per day

          -  Positive stool examination for enteric pathogens, pathogenic ova or parasites, of
             Clostridium difficile at Screening

          -  Karnofsky Performance Status ≤ 60%

          -  Presence of any clinically significant laboratory, medical history, or physical
             examination findings deemed unacceptable by the Investigator

          -  A history of short bowel syndrome

          -  History of constipation within 2 years of Screening

          -  Life expectancy &lt; 12 months from Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Fleming, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanna Jackson, Clinical Trial Mgr</last_name>
    <phone>281-863-3484</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Kogara</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Basingstoke Hampshire</city>
        <zip>RG249NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV22DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE59RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M204BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
